

ORIGINAL RESEARCH

Comparative Study of Granisetron and Butorphanol To Control Intraoperative Shivering Under Spinal Anaesthesia

¹Dr. Pratibha S D, ²Dr. Geetha S Hasaraddi, ³Dr. Renuka Holyachi, ⁴Dr. Shivanand LK, ⁵Dr. Vidya Patil

^{1,4}Associate Professor, ^{3,5}Professor, Department of Anaesthesiology, BLDEDU's Shri BM Patil Medical College Hospital and Research Center, Vijayapur, Karnataka, India

²Associate Professor, Department of Anaesthesiology and critical care, Navodaya Medical College, Raichur, Karnataka, India

Corresponding Author

Dr. Shivanand LK

Associate Professor, Department of Anaesthesiology, BLDEDU's Shri BM Patil Medical College Hospital and Research Center, Vijayapur, Karnataka, India

Email: shivanandkarigar82@gmail.com

Received: 21 February, 2023

Accepted: 26 March, 2023

ABSTRACT

Introduction: Shivering is a physiological response due to thermoregulatory mechanism to cold which is an involuntary, muscular twitching. It is usually observed during spinal and epidural anaesthesia administration. Surgery causes heat loss due to exposure to environment, evaporation of body heat and infusion of intravenous fluids which causes reduction in core body temperature. There is reduction in core body temperature due to altered afferent thermal input from the blocked region. This study was done to evaluate the efficacy of granisetron and butorphanol to control shivering intraoperatively who undergo spinal anaesthesia. **Methods:** This study included 62 adult patients, 31 patients in group G and 31 patients in group B. Patients with American society of Anaesthesiologists (ASA) physical status I and II, aged 20-60 years, either gender who were scheduled for lower abdominal surgeries under spinal anaesthesia were included in the study. Vital parameters and grades of shivering were observed. **Results:** We observed onset of action of butorphanol was within 3-5 minutes while it took 5-7 minutes for granisetron to provide relief from shivering, making the time of onset of action statistically significant. There was significant statistical difference in Heart rate between two groups at 5mins 10mins and 30 mins. There was difference between Mean arterial pressure (MAP) between both groups at 10mins and 30mins was also found to be significant statistically. **Conclusion:** The incidence of tachycardia, hypotension and vomiting was significantly higher with butorphanol when compared to Granisetron. Butorphanol onset of action was faster with mild sedative effects. Thus Granisetron is superior to butorphanol in control of shivering.

Keywords: Shivering, granisetron, butorphanol, spinal anaesthesia.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

INTRODUCTION

Shivering is a physiological response due to thermoregulatory mechanism to cold which is an involuntary, muscular twitching. It is usually observed during spinal and epidural anaesthesia administration¹. Surgery causes heat loss due to exposure to environment, evaporation of body heat and infusion of intravenous fluids which causes reduction in core body temperature. There is reduction in core body temperature due to altered afferent thermal input from the blocked region^{2,3}. Shivering is observed in more than 50% of the patients who undergo neuraxial blockade. Due to increase in oxygen consumption and increase in carbon dioxide production there is arterial hypoxemia. There is mismatch between oxygen supply and demand ratios

causing lactic acidosis^{4,5}. Hemodynamic are altered with heart rate variability and myocardial infarction in cardiac compromised patients. It also interferes in blood pressure, increases intracranial pressure, blood coagulopathy, decreased immunity and chances of surgical site infection which causes delay in wound healing. Shivering is unpleasant and increases anxiety in patients intraoperatively.

Serotonin (5-hydroxytryptamine), an amine is present in the brain and spinal cord which has an important role in neuronal transmission⁶. Few studies have found serotonergic system has some role in controlling shivering intraoperatively. A serotonin 5-HT₃ receptor antagonist inhibits the uptake of serotonin in the preoptic anterior hypothalamic region, which influences both heat production and heat loss^{7,8}.

In our present study granisetron can reduce intra-operative shivering.

Butorphanol is a centrally acting opioid analgesic with kappa and mu receptors agonistic modulation has ant shivering property.

This study is done to evaluate the efficacy of granisetron and but orphanol to control shivering intraoperatively who undergo spinal anaesthesia.

MATERIALS AND METHODS

The study was done after obtaining institutional committee approval. Written consent was taken from all patients after explaining the study protocol.

This randomized prospective clinical study included 62 adult patients (31 in each group) and were allocated into two groups by computerized random number table. Patients with American society of Anaesthesiologists (ASA) physical status I and II, aged 20-60 years, either gender who were scheduled for lower abdominal surgeries under spinal anaesthesia were included in the study. Patients with any contraindication to spinal anaesthesia, thyroid disorders, morbid obesity, cardiopulmonary diseases, temperature $>38^{\circ}\text{C}$ and $<36^{\circ}\text{C}$ and caesarean section were excluded from the study.

In group G patients received Granisetron 40mcg Intravenous (IV) and Group B patients received Butorphanol 0.01mg/kg IV when patient developed shivering intraoperatively which lasted more than two minutes.

Pre-operative evaluation included history of underlying medical illness, previous history of surgery, anesthetic exposure and hospitalization. Physical examination included general condition of the patient, Vital signs- heart rate (HR), blood pressure, respiratory rate, height and weight. Cardiovascular system, respiratory system, central nervous system, spine examination and airway assessment by Mallampati grading was done. Investigations such as complete blood count, bleeding time, clotting time, blood glucose, blood urea, serum creatinine. Chest x-ray and electrocardiography (ECG) were done if required.

All patients were kept nil by mouth the night before surgery for 8 hours.

On day of surgery baseline vital parameters were recorded in the preoperative room.

On the operating table all monitors were attached like pulse oximeter, non-invasive blood pressure (NIBP) and ECG. IV line was secured with 20 G cannula. All patients were preloaded with 500ml Ringer lactate solution at room temperature. Baseline temperature was recorded using a mercury thermometer placed in the axillary region. Operating theatre temperature was maintained at 22-25 C.

Under aseptic precautions all patients were administered spinal anaesthesia in left lateral or in sitting position with 26 G Quincke needles in L3-L4 lumbar space. Hyperbaric bupivacaine 0.5% was injected with dose of 15-20mg according to the type

and duration of the surgery. Surgical drapes were used to completely wrap all patients. Other warming methods were not employed.

In our study, patients who began to shiver for two minutes after receiving spinal anaesthesia such patients data were collected.

Grade -0 -No shivering, grade -1- piloerection, peripheral vasoconstriction, peripheral cyanosis without other cause but without visible muscular activity, grade-2 -Visible muscular activity confined to one muscle group, grade-3- visible muscular activity in more than one muscle group, grade-4-gross muscular activity involving the entire body

According to the 5 item Shivering scale, shivering with grades two or more medical intervention was carried out.

Patients were randomly assigned to one of the two study groups,. Granisetron 40 mcg/kg in Group G and Butorphanol 0.01 mg/kg in Group B. When patients experienced shivering of the above mentioned grades for a minimum of two minutes from the commencement of the shivering axillary temperature was recorded.

The study medication was then injected slowly over a 30-second period. A timer was used to precisely record the period of time between administration of the drug and the patient's shivering cessation. Initial action of the patient to the drug was graded as either Success (shivering absent) or Nil (shivering intensity not controlled).

All patients were observed for grades of shivering, heart rate, oxygen saturation, NIBP, temperature for a period of 1 minute for the first 5 minutes and later it was observed for 10, 20 and 30 minutes till shivering stopped.

All patients were observed for reappearance of shivering, sedation score, failure of drug action and adverse reactions such as nausea, vomiting, pruritus, respiratory depression, bradycardia, and hypotension. Bradycardia was taken as a heart rate below 60bpm, and respiratory depression as a respiratory rate less than 10 cycles per minute.

Modified Ramsay's sedation scale was used to measure the level of sedation.

Score 1- Awake and alert, no cognitive impairment.

Score 2- Awake but tranquil, purposeful responses to verbal commands at conversation level.

Score 3- Appears asleep, purposeful responses to verbal commands at the conversation level.

Score 4- Appears asleep, purposeful responses to verbal commands but at louder than usual conversation level or requiring light glabellar tap.

Score 5- Asleep, sluggish purposeful responses only to loud verbal commands or strong glabellar tap.

Score 6- Asleep, sluggish purposeful responses only to painful stimuli.

Score 7- Asleep, reflex withdrawal to painful stimuli only.

Score 8- Unresponsive to external stimuli, including pain.

Above 5 and 6 are considered as satisfactory sedation levels

Drug which was administered stopped shivering that particular drug was considered to be effective treatment of shivering. Reappearance of shivering or incomplete cessation of shivering was treated with other modalities like warm fluid therapy and drug therapy such as Injection tramadol 50mg IV and Injection Dexamethasone 8mg IV, and the test medication was deemed ineffective in these cases.

STATISTICAL ANALYSIS

On the basis of a study conducted by AsthaPalan et al⁹, anticipated mean± SD of butorphanol and tramadol for shivering is 98.36+ or – 0.40 and 98.44 = and – 0.38 respectively. 62 patients of both gender were randomly divided into two groups of 31 in each group. Sample size calculation was done.

To conduct the comparative study of Granisetron versus Butorphanol in controlling intraoperative shivering under spinal anesthesia, 62 patients (31 in each group) are required to have a 90% chance of detecting, a decrease in relief of shivering from 63%

in the G group to 23% in the B group, at 5% significant level.

All characteristics are summarized descriptively. The summary statistics of n, mean, and standard deviation (SD) will be utilised for continuous variables. In the data summaries for categorical data, the number and percentage will be utilised, and the data will be examined using the Chi-Square test for association, the t test to compare means, the ANOVA, and diagrammatic presentation. All data was entered in a Microsoft Excel sheet, and for analysis SPSS 22 version software was used. Frequencies and proportions were used to represent categorical data. For qualitative data, the chi-square test was utilised as a significance test. Standard deviation and mean were used to describe continuous data. Independent t test was used as a test of significance to determine mean difference between two quantitative variables.

RESULTS

In this study, there was no statistically significant difference between the groups with respect to demographic data and body temperature (Table-1)

Table 1: Demographic Data

| | GROUP G (n=31) | GROUP B(n=31) | p value |
|----------------------------------|----------------|---------------|---------|
| Age (Mean±SD) | 37.965±9.861 | 36.258±10.84 | 0.519 |
| Gender Female | 11(35.48%) | 12(38.7%) | - |
| Male | 20(64.51%) | 19(61.29%) | - |
| ASA Grading -1 | 20(64.52%) | 18(58.06%) | - |
| ASA Grading -2 | 11(35.48%) | 13(41.94%) | - |
| Body temperature(Mean±SD) | 37.051±9.841 | 38.038±10.841 | 0.708 |

Data is represented as numbers and n(%), *p value- <0.05 significant, Group G- Granisetron, Group B- Butorphanol.

The grade of shivering were found to be comparable between the two groups with 58.06% in Group G and 48.39% in group B demonstrating grade 3 shivering. It was found that onset of action of butorphanol was within 3-5 minutes while it took 5-7 minutes for granisetron to provide relief from shivering, making the time of onset of action statistically significant (Table-2).

Table 2: Grade and time of onset of shivering

| | GROUP G(n=31) | GROUP B(n=31) | P Value |
|--|---------------|---------------|---------|
| Time of onset of shivering(Mean±SD) | 6.06±0.83 | 3.31±0.86 | <0.01* |
| Grade of Shivering | | | |
| GRADE- 1 | 0 | 0 | - |
| GRADE 2 | 3(9.68%) | 5(16.13%) | |
| GRADE 3 | 18(58.06%) | 15(48.39%) | |
| GRADE 4 | 10(32.26%) | 11(35.48%) | |

Data is represented as numbers and n(%), *p value- <0.05 significant, Group G- Granisetron, Group B- Butorphanol.

There was significant statistical difference in Heart rate between two groups at 5mins 10mins and 30 mins (Table-3).

Table 3: Mean heart rate

| TIME | GROUP G n=31 | GROUP B n=31 | p Value |
|----------------|--------------|--------------|---------|
| Mean±SD | | | |
| 1 min | 96.02±2.36 | 97.45±8.58 | 0.374 |
| 3 mins | 95.18±2.37 | 94.87±3.47 | 0.682 |

| | | | |
|---------|------------|------------|-------|
| 4 mins | 96.18±2.37 | 97.7±8.63 | 0.348 |
| 5 mins | 92.09±0.43 | 93.18±2.11 | 0.006 |
| 10 mins | 85.74±6.55 | 88.66±2.11 | 0.021 |
| 20 mins | 87.83±5.49 | 88.66±2.11 | 0.435 |
| 30 mins | 87.74±4.67 | 89.66±1.11 | 0.029 |

Data is represented as Mean±SD, *p-value- <0.05 significant, Group G- Granisetron, Group B-Butrophanol

There was difference between Mean arterial pressure (MAP) between both groups at 10mins and 30mins was also found to be significant statistically. Slight dip in heart rate was found immediately after the administration of butorphanol while hypotension was only observed 10 min after the administration(Fig 1). No such notable variations in the HR and MAP were observed after the administration of granisteron.




Figure-1- Line diagram showing Mean arterial pressure

However, there was difference in Oxygen saturation (SPO2) at 10 mins and 30mins was found to be significant ststistically between the two groups(Fig 2).




Figure-2 - Line diagram showing oxygen saturation comparison

Grade 3 sedation was observed in all the patients receiving butorphanol whereas grade 2 sedation was noted with granisetron.

Twelve patients who received butorphanol experienced nausea and vomiting during the intra-operative period, while patients who received granisteron had no such complaints. Hence making comparison of the incidence of

side effects between the two groups statistically significant. However, no other side effects were observed (Table-4).

Table 4: Adverse effects

| Complications | GROUP G n=31 | GROUP B n=31 |
|-------------------------|-----------------|-----------------|
| Nausea and vomiting | - | 12(0.001%) |
| Sedation | 6(20%) | 14(45%) |
| Pruritis | - | - |
| Recurrence of shivering | - | - |
| Respiratory depression | - | - |

Data is represented as numbers and n(%), *p value- <0.05 significant.

Group G- Granisetron, Group B-Butrophanol.

DISCUSSION

Shivering is an uncontrollable, oscillatory muscle movement and is a physiological response to hypothermia in an effort to increase metabolic heat generation². Shivering is caused by a reduction in core body temperature, which is caused by a sustained disruption of thermoregulatory autonomic function when under anaesthesia, in addition to infusion of intravenous fluids and low operating room temperature^{10,11}. The most frequent cause of shivering is perioperative hypothermia¹², however it is difficult to determine the precise incidence of each.

When shivering occurs, oxygen demand may rise by 150% to 500%, and carbon dioxide production may also rise linearly^{13,14}. In patients who have decreased myocardial reserve or pre-existing coronary disease shivering exaggerates the condition. Shivering may cause higher wound pain, slower wound healing and a longer recovery time after anaesthesia. It also raises intraocular and intracranial pressure.

Perioperative shivering is a frequent problem that can lead to tachycardia, hypertension, and increased metabolic needs. It impedes with ECG, blood pressure, and oxygen saturation during the intraoperative period¹⁵. Other risk factors for shivering include the type and length of anaesthesia, the degree of sensory blockage, the temperature of the operating room, and fluid infusion. In comparison to propofol, thiopentone was found to cause higher shivering in females and when used after general anaesthesia. Despite the possibility of rigours in the context of normothermia, it typically happens as a physiological response to maintain the core body temperature.

Although it is possible that shivering frequently develops as a defensive mechanism to hypothermia. In our study we observed reduction in temperature during shivering and after treatment of shivering when compared to baseline values. We observed that there was no significant difference in temperature during and after treatment of shivering, indicating that the cessation of shivering was likely caused by the study drugs resetting thermoreceptors at a lower threshold rather than by a change in body temperature.

Pharmacological intervention lowers the shivering threshold rather than raising body temperature, reducing rigours. Opioids, α -2 adrenergic,

serotonergic, and anticholinergic receptors are all implicated in the intricate neurotransmitter pathways that cause shivering. Drugs that affect these systems are used to treat this ailment as a result of this fact.

In our study we observed granisetron to be more effective in controlling shivering over butorphanol. Granisetron and butorphanol both had comparable results in complete suppression of shivering which accords with observations made by D kabade et al¹⁶ concluded that prophylactic granisetron 40ug/kg IV is very effective in control of perioperative shivering following spinal anaesthesia and also reduces the need for antiemetic.

Similar studies by Saito et al¹⁷, showed that impaired thermoregulation under spinal anaesthesia makes hypothermia more likely to occur quickly. The shivering threshold will be achieved earlier and more shivering will be needed to prevent additional hypothermia as a result of the rapid temperature drops that occur during spinal anaesthesia.

We also observed in our study the sedation caused by butorphanol was 20% more compared to granisetron which was 6%. In our study we found 12 patients had nausea /vomiting in group B when compared to no nausea/vomiting in Group G. Some studies showed that ondansetron and granisetron are very effective in treatment of nausea, vomiting in caesarean section patients under spinal anaesthesia which correlated with our study^{18,19,20}.

Similar studies done by Wang Y et al²¹ studied on different doses of butorphanol and found to effectively prevent recurrence of shivering in post operative period which provided good postoperative analgesia and recovery.

Astha Palan et al⁹ compared butorphanol with tramadol to control intraoperative shivering under spinal anaesthesia and concluded that butorphanol is better in treatment of shivering during regional anaesthesia when compared to tramadol due its fast onset of action and less adverse reactions.

Krithika V et al²² compared tramadol and butorphanol for control of shivering and concluded that butorphanol is effective compared to tramadol in treatment of postoperative shivering due to fast onset of action, high success rate and less recurrence.

LIMITATIONS OF THE STUDY

A large sample size can predict more accurate results. Due to differences in body habitus and individual tolerance to temperature differences, the findings of our study might not be congruent with those of studies conducted on other ethnic communities.

CONCLUSION

The incidence of tachycardia, hypotension and vomiting was significantly higher with butorphanol when compared to Granisetron. Butorphanol onset of action was faster with mild sedative effects. Thus Granisetron is superior to butorphanol in control of shivering.

REFERENCES

- Rai S, Verma S, Pandey HP, Yadav P, Patel A. Role of butorphanol and ondansetron premedication in reducing postoperative shivering after general and spinal anesthesia: A randomized comparative study from North India. *Anesth Essays Res.* 2016;10(2):319-323. doi:10.4103/0259-1162.172724.
- Joshi SS, Arora A, George A, Shidhaye RV. Comparison of intravenous butorphanol, ondansetron and tramadol for shivering during regional anesthesia: A prospective randomized double-blind study. *Anaesth Pain Intensive Care.* 2013;17:33-9.
- Alfonsi P. Postanaesthetic shivering: epidemiology, pathophysiology, and approaches to prevention and management. *Drugs.* 2001;61:2193-205.
- Maheshwari SB, Shah KS, Chadha IA. Tramadol and butorphanol for control of shivering: Randomized double blind comparative study. *J AnaesthesiolClinPharmacol.* 2008;24:343-6.
- Buggy DJ, Crossley AW. Thermoregulation, mild perioperative hypothermia and postanaesthetic shivering. *Br J Anaesth* 2000;84:615-28.
- Bhattacharya PK, Bhattacharya L, Jain RK, Agarwal RC. Post anaesthesia shivering (PAS): A review article. *Indian J Anaesth* 2003;47:88-93.
- Iqbal A, Ahmed A, Rudra A, Wankhede RG, Sengupta S, Das T, et al. Prophylactic granisetron vs pethidine for the prevention of postoperative shivering: A randomized control trial. *Indian J Anaesth* 2009;53:330-4.
- Mohammadi SS, Jabbarzadeh S, Movafegh A. Mohammadi SS, Jabbarzadeh S, Movafegh A. Efficacy of granisetron on prevention of shivering, nausea and vomiting during caesarean delivery under spinal anesthesia: A randomized double-blinded clinical trial. *J ObstetAnaesthCrit Care* 2015;5:22-6.
- Astha Palan, N.K Agrawal, Control of intraoperative shivering under spinal anaesthesia- a prospective randomized comparative study of butorphanol with tramadol, *Journal of Krishna institute of medical sciences university*, 6(1), January-March 2017.
- Sajedi P, Yaraghi A, Moseli HA. Efficacy of granisetron in preventing postanesthetic shivering. *ActaAnaesthesiol Taiwan* 2008;46(4):166-70.
- Kranke P, Eberhart LH, Roewer N, Tramèr MR. Pharmacological treatment of postoperative shivering: A quantitative systematic review of randomized controlled trials. *AnesthAnalg* 2002;94:453-60.
- De Witte J, Sessler DI. Perioperative shivering: physiology and pharmacology. *Anaesthesiology.* 2002;96:467-484
- Zhang Y, Wong KC. Anesthesia and postoperative shivering: its etiology, treatment and prevention. *ActaAnaesthesiol Sin.* 1999;37:115-120.
- Katyal S, Tewari A, et al. Shivering: anesthetic considerations. *J AnaesthClinPharmacol.* 2002;18:363-376.
- Bansal P, Jain G. Control of shivering with clonidine, butorphanol, and tramadol under spinal anesthesia: a comparative study. *Local Reg Anesth* 2011;4:29-34.
- Kabade SD, et al. Comparative study of granisetron versus pethidine for the prevention of perioperative shivering under spinal Anesthesia. *Karnataka Anaesth J* 2016;2:14-8.
- Saito T, Sessler DI, Fujita K, Ooi Y, Jeffrey R. Thermoregulatory effects of spinal and epidural anesthesia during cesarean delivery. *Reg Anesth Pain Med* 1998;23:418-23.
- Moola S, Lockwood C. Effectiveness of strategies for the management and/or prevention of hypothermia within the adult perioperative environment. *Int J Evid Based Healthc.* 2011;9:337-45.
- Crowley LJ, Buggy DJ. Shivering and neuraxial anesthesia. *Reg Anesth Pain Med* 2008 MayJun;33(3):241-52.
- Sheikh Mustak Ali, Manjubala Acharya. Comparative study of tramadol with that of butorphanol for the control of shivering in patients undergoing neuraxial blockade. *Int J Res Prof.* 2016;2(5):50-55.
- Wang Y, et al. Effect of Different Doses of Butorphanol on Postoperative Shivering in Elderly Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. *Drug Des DevelTher.* 2023;17:839-849.
- V. Krithika, R Selvarajan, S Nienna. Control of shivering with butorphanol and tramadol under spinal anesthesia-a comparative study. *International J of Scientific Study.* 2017;5(3):98-100.